- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00004037
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
Evaluation of Docetaxel in Recurrent, Platinum Resistant, Refractory and Paclitaxel Refractory Ovarian Cancer and Primary Peritoneal Carcinoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with recurrent or refractory ovarian or primary peritoneal cancer.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES: I. Estimate the antitumor activity of docetaxel in patients with paclitaxel- and platinum-resistant, recurrent or refractory, ovarian epithelial or primary peritoneal cancer who have failed on higher priority treatment protocols. II. Determine the nature and degree of toxicity of docetaxel in this patient population.
OUTLINE: Patients receive docetaxel as a 1 hour continuous intravenous infusion. Courses are repeated every 21 days. Treatment continues in the absence of unacceptable toxic effects or disease progression. All patients are followed every 3 months for 2 years, every 6 months for 3 years, and then until death.
PROJECTED ACCRUAL: A total of 23-56 patients will be accrued for this study.
Studietype
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 3N6
- NCIC-Clinical Trials Group
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294
- University of Alabama Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85006-2726
- CCOP - Greater Phoenix
-
-
California
-
Los Angeles, California, Verenigde Staten, 90033-0800
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, Verenigde Staten, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Orange, California, Verenigde Staten, 92868
- Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Verenigde Staten, 94304
- Women's Cancer Center
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80262
- University of Colorado Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, Verenigde Staten, 20307-5000
- Walter Reed Army Medical Center
-
Washington, District of Columbia, Verenigde Staten, 20007
- Vincent T. Lombardi Cancer Research Center, Georgetown University
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Emory University Hospital - Atlanta
-
Atlanta, Georgia, Verenigde Staten, 30342-1701
- CCOP - Atlanta Regional
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96813
- MBCCOP - Hawaii
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Rush-Presbyterian-St. Luke's Medical Center
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago Cancer Research Center
-
Evanston, Illinois, Verenigde Staten, 60201
- CCOP - Evanston
-
Springfield, Illinois, Verenigde Staten, 62526
- CCOP - Central Illinois
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202-5265
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa Hospitals and Clinics
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536-0084
- Albert B. Chandler Medical Center, University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins Oncology Center
-
Bethesda, Maryland, Verenigde Staten, 20892
- Radiation Oncology Branch
-
Bethesda, Maryland, Verenigde Staten, 20892
- Medicine Branch
-
-
Massachusetts
-
Worcester, Massachusetts, Verenigde Staten, 01655
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- CCOP - Ann Arbor Regional
-
Detroit, Michigan, Verenigde Staten, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- University of Minnesota Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39216-4505
- University of Mississippi Medical Center
-
Keesler AFB, Mississippi, Verenigde Staten, 39534-2576
- Keesler Medical Center - Keesler AFB
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59101
- CCOP - Montana Cancer Consortium
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68131
- CCOP - Missouri Valley Cancer Consortium
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89106
- CCOP - Southern Nevada Cancer Research Foundation
-
-
New Jersey
-
Camden, New Jersey, Verenigde Staten, 08103
- Cooper Hospital/University Medical Center
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Cancer Center of Albany Medical Center
-
Brooklyn, New York, Verenigde Staten, 11203
- State University of New York Health Science Center at Brooklyn
-
Manhasset, New York, Verenigde Staten, 11030
- North Shore University Hospital
-
New York, New York, Verenigde Staten, 10021
- Memorial Sloan-Kettering Cancer Center
-
Rochester, New York, Verenigde Staten, 14642
- University of Rochester Cancer Center
-
Stony Brook, New York, Verenigde Staten, 11790-9832
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham, North Carolina, Verenigde Staten, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Verenigde Staten, 27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
Winston-Salem, North Carolina, Verenigde Staten, 27103
- Brookview Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Barrett Cancer Center, The University Hospital
-
Cleveland, Ohio, Verenigde Staten, 44195
- Cleveland Clinic Cancer Center
-
Cleveland, Ohio, Verenigde Staten, 44106-5065
- Ireland Cancer Center
-
Columbus, Ohio, Verenigde Staten, 43210
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73190
- University of Oklahoma College of Medicine
-
Tulsa, Oklahoma, Verenigde Staten, 74136
- CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97213
- CCOP - Columbia River Program
-
-
Pennsylvania
-
Abington, Pennsylvania, Verenigde Staten, 19001
- Abington Memorial Hospital
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, Verenigde Staten, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Pennsylvania Hospital
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- University of Pennsylvania Cancer Center
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425-0721
- Medical University of South Carolina
-
Spartanburg, South Carolina, Verenigde Staten, 29303
- CCOP - Upstate Carolina
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten, 38117
- CCOP - Baptist Cancer Institute
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235-9154
- Simmons Cancer Center - Dallas
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas - MD Anderson Cancer Center
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22908
- Cancer Center, University of Virginia HSC
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98195-6043
- University of Washington Medical Center
-
Tacoma, Washington, Verenigde Staten, 98405
- Tacoma General Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS: Histologically confirmed recurrent or refractory ovarian epithelial or peritoneal cancer Platinum resistant AND paclitaxel resistant Progressed on or within 6 months of completing therapy with paclitaxel and platinum either alone or in combination Bidimensionally measurable disease (excludes ascites and pleural effusions) Brain metastases allowed provided that other measurable disease exists and brain lesions required no therapy for 6 months and are not life threatening Not eligible for higher priority GOG protocol
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy: At least 8 weeks Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT/SGPT no greater than 1.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL Other: No significant infection Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No history of allergic reaction to polysorbate 80 (e.g., etoposide or vitamin E) No other invasive malignancies within the past 5 years except nonmelanoma skin cancer
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics Must have had at least 1 prior platinum based chemotherapeutic regimen containing carboplatin, cisplatin, or another organoplatinum compound Must have had at least 1 prior paclitaxel based chemotherapeutic regimen 1 or 2 prior chemotherapy regimens containing platinum and paclitaxel allowed Recovered from toxic effects No prior docetaxel Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: Recovered from effects of recent surgery Other: At least 3 weeks since any prior therapy directed at the malignant tumor No prior cancer treatment that contraindicates this protocol therapy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Peter G. Rose, MD, The Cleveland Clinic
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Urogenitale neoplasmata
- Neoplasmata per site
- Carcinoom
- Neoplasmata, glandulair en epitheel
- Genitale neoplasmata, vrouwelijk
- Endocriene systeemziekten
- Ovariële ziekten
- Adnexale ziekten
- Gonadale aandoeningen
- Endocriene klierneoplasmata
- Ovariumneoplasmata
- Carcinoom, ovariumepitheel
- Moleculaire mechanismen van farmacologische werking
- Antineoplastische middelen
- Tubuline-modulatoren
- Antimitotische middelen
- Mitose modulatoren
- Docetaxel
Andere studie-ID-nummers
- CDR0000066369
- GOG-126J
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .